Cancer stem cells (CSCs) are found in many cancer types, including breast carcinoma. Breast cancer stem cells (BCSCs) are considered as seed of cancer formation and they are associated with metastasis and genotoxic drug resistance. Several studies highlighted the presence of BCSCs in tumor microenvironment and they are accentuated with several carcinoma events including metastasis and resistance to genotoxic drugs and they also rebound after genotoxic burn. Stemness properties of a small population of cells in carcinoma have provided clues regarding the role of tumor microenvironment in tumor pathophysiology. Hence, insights in cancer stem cell biology with respect to molecular signaling, genetics and epigenetic behavior of CSCs have been used to modulate tumor drug resistance due to genotoxic drugs and signaling protein inhibitors. This review summarizes major scientific breakthroughs in understanding the contribution of BCSCs towards tumor's capability to endure destruction inflicted by molecular as well as genotoxic drugs.
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Background
Breast cancers are reported to be the cause for death of 800,000 women every year in the world. 1 It is estimated that by 2030, the number of women diagnosed every year with breast cancer could almost double to 3.2 million. 2 Within the existing regimens of cancer treatment options including surgery, chemotherapy, radiotherapy and hormonal therapy, therapeutic bottlenecks such as drug resistance, metastasis and relapse are frequently associated and witnessed.
Several genetic studies support the idea of intra-tumoral heterogeneity in breast cancer stem cells (BCSCs) contributed by genetic alterations. [3] [4] [5] Besides, BCSCs may also carry heritable epigenetic alterations, which may serve equally well to generate phenotypically distinct subpopulations within tumors. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] With an increasing understanding about heterogeneous nature of tumors including breast carcinoma, the existence of small cancer stem cells (CSCs) population with low proliferation rate and vibrant tumorigenic potential is suggested as a platform for cancer development, metastasis and resistance to genotoxic approaches. 11, 15, [17] [18] [19] [20] [21] [22] [23] [24] In this review, we highlight the implications of BCSCs in the development of therapeutic drug resistance, and recent intervention strategies including clinical trial status for breast carcinoma. We begin with an introduction on molecular phenotypes of BCSCs, followed by conducive microenvironment, state of deregulation of signaling pathways, role of BCSCs in drug resistance, epigenetic regulation and status on therapeutic interventions of BCSCs for cancer treatment.
Molecular Distinction in BCSCS Phenotypes
There is a clear understanding that a small subpopulation of cells within breast tumor community behave as tumorinitiating cells or BCSCs. These BCSCs are endowed with infinite proliferation potential through self-renewal and transient differentiation. 7, 9, 12, 25, 26 These cancer initiating cells comprising of various sub-populations of BCSCs have been suggested to give rise to a number of clonal and non-clonal cells that are heterogeneous in nature. These cells due to their indefinite potential of cell division divide continuously to form a heterogeneous tumor mass. Among BCSC subpopulation, two distinct molecular phenotypes namely CD441/CD242/low and CD441/CD241 have been identified. [27] [28] [29] [30] A pioneering work by Al-Hajj et al. described for the first time the CD441/CD242/low subpopulation of breast cancer cell, which was originally found in metastatic pleural effusions of breast carcinoma patients and commonly referred as BCSCs. 27 Earlier evidences have indicated that the percentage of CD441/CD24-/low is higher in breast cancer cell population and it varies in different types of breast tumors like basal type (37-97%) and luminal type (0-17%). [28] [29] [30] On the other side, another sub-population within BCSCs as CD441/CD241, which is commonly referred as progeny from CD441/CD24-/low BCSC subpopulation has been reported to be present in breast cancer cell population ranging from 0 to 90% (basal type) and 0 to 15% (luminal type). phenotype CD441/CD242/low have been suggested as seeding cells to form a secondary (recurrent or metastatic) tumor 7, 9, 12, 25, 26 ( Fig. 1) . In other experimental findings, these BCSCs with CD441/CD242/low phenotype are found to be endowed with the ability to seed tumors in mice and to have self-renewal tendency. Further, CD24 has been found to be heavily glycosylated that can bind to P-selectin expressed on Additionally, CD44 is also defined as a transmembrane glycoprotein with a clear role in cell-cell and cell-matrix adhesion interactions, and cell migration. However, there are certain controversies regarding the claim that CD24 is not a consistent breast cancer stem cell marker and its direct role in tumorigenicity is not convincing. 15, 20, 31, 32 Further, evidence suggests that the CD441/CD242/low phenotype may not be sufficient to characterize BCSCs. 15, 20, 31, 32 There are reports on the expression of integrins such as CD29 (b1), CD49f and CD61 (b3), which are only marginally expressed in normal mammary epithelia. 33, 34 Several experimental data suggest that CD133 named as prominin-1 is recognized in a subgroup of breast CSC. Also the expression level ofCD131 has been found to be more distinct in BCSCs in comparison with other CSC markers such as CD44 and ALDH. 15, 20, 31, 32 Another BCSC marker, which is reported as aldehyde dehydrogenase (ALDH) enzyme has been shown to be involved in the detoxification process. It is suggested to be an independent prognostic factor for BCSCs heterogeneity at the metastatic site. 35 Several studies using breast cancer mammary models emphasized on significant enrichment of CD44 1 / CD24-/low cells due to chemotherapy treatment. [11] [12] [13] [14] [15] [16] In one study, eight human breast cell lines (human mammary epithelial cells, and MCF10A, MCF7, SUM149, SUM159, SUM1315 and MDA-MB-231 cells) were subjected to flow cytometry for CD44, CD24, and epithelial-specific antigen (ESA) expression. 36 These findings clearly led to the conclusion that a small breast cancer cell population with CD441/CD24-/ESA1 can self-renew and preferentially survive chemotherapy. 36 Currently, CSC marker CD133 is rated as an attractive target in therapeutic intervention. 15, 16, 36 Earlier molecular evidences suggest that BCSC phenotype is specified by the presence of Kruppel-like factor 4 (KLF4), octamer-binding transcription factor 4 (OCT4), SRY-box 2 (SOX2), and NANOG. [37] [38] [39] Duru et al. provided data to support that in case of BCSCs, HER2-associated protein profile including effectors may be involved in tumor metastasis, apoptosis, mitochondrial function, and DNA repair. Their findings suggested that HER2-mediated pro-survival signaling network may contribute to aggressive phenotype of BCSCs which could be targeted to control therapy-resistant HER2 (-/low) breast cancer. 40 In line with potential marker proteins, there is report on elevated levels of type II transglutaminase (TG2) in CSCs derived from several cancers. TG2 is reported to be an important breast cancer cell survival factor and is a marker for high risk cancer recurrence. 41 Among cancer stem cell (CSC) molecular markers, several are being considered for their use as potential targets for developing new therapies to impede regeneration of CSCs and cancer relapse. [13] [14] [15] 20, 31, 32 In summary, BCSCs have been endowed with extraordinary capabilities including self-renewal, and expression of unique set of markers, transcription factors, enzymes, etc. In recent, despite growing understanding about the presence and role of distinct set of markers to achieve BCSCs phenotypes, the clinical evidences are lacking to support the link between stemness and associated molecular players.
BCSCS and Their Conducive Cellular Neighborhood
CSC niches are a component of the tumor microenvironment (TME) and are morphologically and physiologically different from other regions. These niches play a major role in the maintenance of CSC stemness properties like self-renewal, self-differentiation and tumorigenic. Beyond the maintenance of CSC stemness, they have been suggested to be instrumental in leading to the production of prolonged progenitor, metastasis, phenotypicplasticity properties and immune protection. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Among BCSC niche community members, cancerassociated fibroblasts (CAFs) are enriched in C-X-C Motif Chemokine Ligand 12 (CXCL12), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and hepatocyte growth factor (HGF). CAFs along with other cells in the niche activate stemness through the activation of WNT and NOTCH pathways. [40] [41] [42] CAFs change the functioning of CSC by increasing the levels of CXCL12 and MMP-1 by promoting EMT of CSCs. CAFs also increase chances of metastasis by playing a role in maintenance of metastasis. 43 As an evidence of link between fibroblasts and BCSCs, findings suggest that periostin (POSTN) released by lung stromal fibroblasts can create a favorable metastatic niche. 44 Several studies show that CAF derived factors lead stimulatory effect on stem cell properties of breast cancer cells. 11, 19, 22, 24, [42] [43] [44] Further, CAFs are suggested as potential modulators of stem cell properties of cancer cells and they may be responsible for tumor cell dissemination and metastasis. 45 Tumor-associated macrophages (TAM) and tumorassociated neutrophils (TAN) have been suggested to decrease immune system activity by secreting TGF-b, which activates T regulatory cells (T reg ) by resulting into immune downregulation. 46 These groups of cells associate themselves to CSC-niche via juxtacrine signaling. Myeloid derived suppressor cells (MDSCs) comprise a diverse population of cells originated through monocytic and granulocytic lineages. These cells secrete IL6, TGF-b and various other cytokines leading to inhibition in the activity of immune system. 47 TME, TAMs and CD41 T cells being inflammatory in nature have been reported to increase NF-jB signaling to initiate Slug, Snail and Twist mediated self-renewal pathway in cancer.
46-48 TME and TAM have been suggested to induce EMT and promote migration and invasion of CSCs. 49 There is evidence that the association of TAM and BCSCs are mediated through elevated expression of CD90/Thy1 and EphA4 cell surface protein markers and which may activate Src and NF-jB signaling pathway to sustain stem cell niche maintenance. 49, 50 In summary, the ability of a specific BCSC neighborhood to provide the conducive environment in which this population can make a choice for either self-renewal or tumor differentiation is considered as a critical aspect of cancer biology. Further, there is an urgent need to pay attention to the molecular drug inhibitory approaches to mold the contribution of BCSCs in tumor formation, drug resistance and recurrence.
Deregulated Signaling Pathways in BCSC
Several gene mutations and perturbations in signaling network lead to the development of several types of breast cancer. 7, [51] [52] [53] [54] In principle, well characterized developmental pathways such as the Wnt (Wingless-Int), Shh (sonic hedgehog), Notch, and BMP/TGF-b (bone morphogenetic proteins/transforming growth factor b) are linked to direct proliferation and differentiation of normal stem cells. 8, 11, 22, 24, 26, [54] [55] [56] [57] [58] However, emerging knowledge supports that deregulation of these major signalling pathways may contribute to the self-renewal, EMT process and drug resistance of BCSCs and other CSCs. 11, 19, 22, 24, 57 Wnt signaling and BCSCs
The Wnt signaling pathways are described as a group of signal transduction pathways to pass signals into a cell through cell surface receptors. There are descriptions of three types of pathways such as canonical Wnt pathway, the non-canonical planar cell polarity pathway, and the non-canonical Wnt/calcium pathway. 59, 60 As a common platform, its activation is facilitated through binding of a Wnt-protein ligand to a Frizzled family receptor, which transfers the signal to the Disheveled protein in the cytoplasmic side (Supplementary material Fig. S1 ). [59] [60] [61] [62] [63] [64] The canonical Wnt pathway is suggested to participate in the regulation of gene transcription and may involve paracrine and autocrine signaling. There are various types of cytoplasmic and nuclear b-catenin antagonists which oppose Wnt/b-catenin pathway such as secreted frizzled receptor proteins (SFRPs), Dickkopf (DKK) and chibby, inhibitor of catenin (ICAT) respectively. [61] [62] [63] In BCSCs, the cytoplasmic b-catenin antagonists (SFRPs, DKK) are silenced due to methylation by DNA methyl transferase (DNMT) leading to an increase in Wnt/b-catenin pathway. Chibby and ICAT inhibit binding of b-catenin to TCF. They are also silenced leading to upregulation of oncogenes. 61, 63 The importance of Wnt signaling in carcinogenesis is well known and besides it is also pivotal in embryonic development, cell fate specification, cell proliferation and cell migration. 59, 60 Among possible molecular regulatory mechanisms, DNp63, an isoform of Trp63 transcription factor supports the activities of both normal and malignant mammary tissues by modulating Wnt signaling pathway. 64 In one article while elucidating the Wnt signaling, it is suggested that Nestin (a type VI intermediate filament protein) can control the growth, survival and metastatic ability of BCSCs by promoting Wnt/b-catenin pathway activation. Indeed, low expression of Nestin promotes programmed cell death, cell cycle arrest and reduction of BCSCs metastatic ability. 65 Liu et al. (2015) 66 reported that miRNA-1 can bring cell cycle arrest along with significant decrease in metastatic ability and wound healing by directly targeting frizzled receptors and trankyrase (telomere-associated poly-ADP ribose polymerase) in BCSCs. Recently, Wnt/b-catenin signaling has been suggested to involve pyruvate kinase isozymes M2 (PKM2) in the maintenance of cancer stem-cell characteristics. 67 Furthermore, Williams et al. (2015) 58 suggested the contribution of focal adhesion kinase (FAK)-Wnt axis in CSCs maintenance which can be considered as a target to eradicate such cancer cell population. Sun et al. (2016) 68 reported that let-7c may block self-renewal of BCSCs through estrogen-activated Wnt signaling in ER (estrogen receptor-a) positive breast cancer.
Notch signaling and BCSCs
The Notch pathway is defined as a key signaling pathway in embryonic and adult stem cell homeostasis and it plays a pivotal role in regulating proliferation, differentiation, apoptosis, cell-cell communication and other multiple functions. 8, 11, 22, 24, 26, 57, 58, 69 In short, Notch receptors are processed through proteolytic cleavage in a two-step process. After the proteolysis of Notch receptor, Notch intracellular domain (NICD) fraction is released as an intracellular domain that translocates to the nucleus and acts as a transcriptional cofactor for various genes linked to cellular growth and proliferation 8, 11, 22, 24, 26, [56] [57] [58] (Supplementary material Fig. S2 ). In addition, Notch signaling pathways are suggested to have a cancer-specific role in both blood and solid tumors including breast carcinoma. There is an indication that JAG-1 and NOTCH-4 signaling axis is specifically activated in BCSC and drive stemness and drug resistance. 55, 70 NUMB inhibits the entry of NICD into the nucleus. The NUMB protein that down regulates Notch signaling in normal cells has been found to be mutated in BCSCs by miRNA-146a causing inhibition to the functioning of NUMB. Specifically, JAG1 and NOTCH 4 have been reported to be overexpressed in BCSCs. [18] [19] [20] [21] [22] [23] [24] 55, 70, 71 In contrast, Notch has been suggested to side step in both types of regulatory pathways involving both oncogenic and tumor-suppressor linked cellular fate. 70, 71 Boyle et al. (2017) 72 revealed that collaboration between chemokine receptor CCR7 and Notch1 may promote breast cancer maintenance, progression and eventual metastasis possibly through inducing stemness in MMTV-PyMT transgenic mouse model mammary cancer cell subpopulation. In an experimental design, authors claim that MAP17 (PDZKIP1), a small cargo protein overexpressed in tumors can interact with NUMB through the PDZ-binding domain to promote the Notch signaling pathway. This study indicates that such activation of Notch pathway could induce more production of stem cell factors and cancer-initiating-like cells. The implications of MAP17 overexpression and Notch pathway induction are highly correlated in human colon, breast or lung cancer types. 73 
Hedgehog signaling and BCSCs
Hedgehog signaling plays an important role in self-renewal, proliferation, survival, migration and invasion of BCSCs by increasing the number of mammary tumor initiating cells also termed as BCSCs. [18] [19] [20] [21] [22] [23] [24] 74 In total, mammalian Hh ligands, Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh), are reported as precursor proteins that undergo autoproteolytic cleavage to generate an N-terminal signaling protein 75, 76 (Supplementary material Fig. S3 ). The molecular function of Hh protein is achieved by interacting with transmembrane protein, Patched (PTCH), which constitutively represses Hh pathway activity through its interaction with a transmembrane protein Smoothened (SMO). SMO has been suggested to be aberrantly expressed in BCSCs. 77, 78 This signaling pathway has been shown to influence growth, invasion, and metastasis of breast, prostatic, pancreatic, and brain malignancies both in vitro and in vivo. 75, 76 Neuropilin-2, a VEGF receptor enhances GLI-1's expression through Ras/MEK mediated hedgehog signaling. 79 GLI-1 has been shown to be overexpressed in BCSCs. Further, Neuropilin-2, a VEGF has also been found in the lipid bilayer of BCSCs that stimulates a6b1 integrins. These groups of integrin further stimulate focal adhesion kinase leading to activation of the Ras/MEK pathway that binds with GLI-1 leading to GLI-1 sec enhanced expression. [76] [77] [78] [79] [80] Among various molecular mechanisms to link the Shh signaling in BCSCs self-renewal ability, Memmi et al. proposed that p63, a type of transcription factor can regulate the expression of Shh, GLI family zinc finger 2 (Gli2), and Patched1 (Ptch1) possibly by binding to the promoter of three genes. 80 
TGF-b/BMP signaling pathway and BCSCs
The fields of developmental and cancer biology have acknowledged the importance of deregulation of TGF-b superfamily members as Bone morphogenetic proteins (BMPs), TGF-b and GDFs (growth and differentiation factors), in the regulation of embryonic development, organ development, controlling cellular differentiation, proliferation, and apoptosis. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 81, 82 In short, TGF-b and BMP/GDF form homo-and heterodimers that interact with heterodimers of type I and type II receptors to produce signalling complexes, leading to the activation of SMAD transcription factor [81] [82] [83] [84] (Supplementary material Fig.  S4 ). There is evidence to suggest that TGF-b/BMP signaling could induce EMT for the maintenance of BCSCs. 81 In an experimental proof of concept, BMP7 or BMP2/7 heterodimer acts as an antagonist to the pro-tumorigenic and pro-metastatic actions of TGF-b, and reduced TGF-b-driven SMAD signalling and cancer cell invasiveness. 83 Recently, A recent data provides therapeutic and interventional study proof by showing the inhibitory potential of a novel peptide P123 and BMP7 against BMP signaling though activating SMAD 1/5/8 signaling and controlling cell cycle. 84 It has also been suggested that DeltaNp63alpha, an isoform of transcriptional activator of p63 associated to inhibition of BMP signaling and as consequence blocking of self-renewal pathway in BCSCs. 18, [81] [82] [83] [84] Further, their findings substantiate that P123 and BMP7 may block selfrenewal, growth, differentiation (reversal of EMT) and or p63 apoptosis of isolated human breast CSCs. 84 In an experiment, there is data to substantiate the role of Nodal, a TGF-b superfamily protein mediated signaling pathway by overexpressing Smad2/3 in BCSCs. 15, [81] [82] [83] [84] In summary, deregulation of key survival and developmental signaling pathways evidently favor conditions leading to formation of BCSCs, and it has tremendous implications in breast tumor pathophysiological conditions. Given the importance of BCSCs in therapeutic debacles, there is a scope of exciting new discoveries which may have potential clinical therapeutic value.
Evidence of Threads as EMT-Breast Cancer Stemness
The commonly observed features of malignant carcinomas, namely the loss of epithelial traits and the gain of certain mesenchymal ones through EMT cellular programming have been widely documented 85, 86 (Supplementary material Fig.  S5 ). There is a consensus that EMT program may be involved in dissemination process, generating stem-like tumor-initiating cells, metastasis and drug resistance. 85, 86 Interestingly, other biological programs similar to the EMTs have been documented to participate with embryo implantation, embryogenesis, and organ development. 85, 86 Several evidences show a consensus that CSCs are inherited with long-term proliferative potential and ability to regenerate tumors with phenotypically heterogeneous cell types. In breast cancer, these cells often indicate characteristics of cells of EMT. 7, 25, 51, 52, [87] [88] [89] [90] Further, EMT state in breast cancer is linked to CSC properties, self-renewal capabilities, resistance to conventional therapies and post-treatment recurrence. Studies also suggest that EMT may promote acquisition and maintenance of stem cells and initiation of vascular mimicry (VM). 91 An EMT equips carcinoma to acquire properties of tumorinitiating cells (TICs). Recently, methods are described to abolish mesenchymal TICs by converting them into epithelial counter parts that show lack of tumor-initiating ability. [88] [89] [90] The authors reveal that the second messenger, cAMP and the subsequent activation of protein kinase A (PKA) may support mesenchymal-to-epithelial transition (MET). Further, their findings link that PKA activation triggers epigenetic reprogramming of TICs by the histone demethylase PHF2. 92 Additionally, the induction of an immune response and HIF factors in epithelial breast cancer as TNBCs have been reported to contribute to formation of single tumor-initiating cell with stem-like properties and EMT. 93 In a recent evidence, NF-jB has been suggested to induce EMT and also to elevate the expression of the inflammatory cytokines interleukin-1b and interleukin-6. Such function of NF-jB is linked to the activation of TICs and predicted as a target of therapeutic inhibitors in breast cancer therapy. Further, urokinase receptor (uPAR) is reported to promote EMT and develop cancer stem cell-like properties in breast carcinoma. 94 In summary, there are several studies to understand EMT as well as MET transition leading to state of change from BCSCs to tumor heterogeneity. At this time, the contribution of EMT in BCSCs and tumor heterogeneity should be understood with reference to clinical background. In future, emphasis should be given to disrupt the EMT-stemness axis for successful eradication of BCSCs in breast tumor niche.
Extra-Genetic Mirna Contribution in BCSCS
There is an increasing evidence to support intricacies in molecular mechanisms that drive BCSCs. Among several potential players, non-protein-coding RNAs participate in carcinogenesis. 88, [95] [96] [97] [98] These small RNAs such as microRNA's (miRNAs), act as endogenous regulators of gene expression that exert their effect by binding to the 3'-untranslated region (UTR) of large target messenger RNAs (mRNAs). 89, 99 In a recent report, the notion that BCSCs may show a distinct miRNA expression profile compared to non-tumorigenic breast cancer cells is widely accepted. 90 These deregulated miRNAs may act as on comiRNAs or as tumor suppressive miRNAs towards self-renewal, EMT, or stem cell identity maintenance of BCSC community. [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] Besides, potential miRNAs may be involved in increased chemotherapeutic resistance of BCSCs. 96 Furthermore, several studies have documented that selected miRNAs, such as miRNA-200c, miRNA-34a, miRNA-155 and miRNA-181 have been linked to maintenance of stem cell like feature in breast cancer and may influence the response to chemotherapy. 17, 88, 101 In addition to deregulation of miRNAs in normal and tumor tissue, BCSCs are reported to display a unique pattern of miRNA signature. The analysis of miRNA expression in BCSCs showed differential expression of around 37 miRNAs compared to non-stem cancer cells. 88, 101 Among a set of miRNAs, miR-200a family is elucidated to act in the process of EMT in breast cancer. 102 CSCs isolated from breast cancer cell lines have been shown to down regulate let-7 miRNA and possibly can negatively regulate the self-renewal of BCSCs. 17 104 Further, their finding concludes that miRNA-182 silencing is capable of SMAD7 upregulation to suppress TGF-b induced EMT and invasion of cancer cells.
In summary, last decade has seen the emergence of contribution of epigenetic factors contribution in BCSCs linked to drugs resistance, metastasis and reoccurrence of tumor. However, several experimental evidences support the idea of interference of epigenetic modulators and also accept the role of indirect mediators as non-coding small RNAs (miRNAs). In spite of several in vitro experimental data, more clinical patient data will be essential for future consideration of these direct and indirect epigenetic modulators for a complete eradication of BCSCs among breast tumor community.
Epigenetic Alterations in BCSCS
It is highly conceived that the contribution of BCSCs in breast tumorigenesis may be due to altered epigenetic signature. Mostly, epigenetic alterations in breast cancer include global DNA hypomethylation and localized hypermethylation in CpG Islands of tumor suppressor genes and also altered histone acetylation and methylation. 95, 105, 106 The gene DNMT1, a member of epigenetic regulators has been known to catalyze DNA methylation and reported to maintain stemness of BCSCs. 88, [95] [96] [97] [98] DNMT1 is highly expressed in breast cancer tissue compared to healthy adult breast tissue. Another finding supports that high levels of DNMT1 reduce expression of natural tumor suppressor gene ISL1 in stem cells. In a recent report, (HIF)-1a-and HIF-2a-dependent expression of AlkB homolog 5 (ALKBH5), an m(6) A demethylase has been suggested to enhance NANOG mRNA and protein expression. Subsequently, such elevated expression of NANOG is considered as a key factor in the maintenance of BCSCs. 107 Liang et al. (2015) 108 provide evidence to link the epigenetic regulation of TWIST1, a transcription factor associated with breast cancer cell stemness and metastasis by promoting histone H3 acetylation by Metadherin (MTDH).
Among a class of epigenetic regulators, the enhancer of zeste homolog 2 (EZH2) is designated as a methyltransferase which catalyzes lysine 27 methylation in histone H3 resulting in suppression of target gene expression. EZH2 is a member of the polycomb group of proteins which regulates cell type identity. EZH2 expression has been found to be elevated in breast carcinoma and linked to maintenance of BCSCs. 109 There is an evidence to show that differentiation genes are marked with H3K27me3 via Polycomb Repressive Complex 2, which is one of the two classes of polycomb-group (PcG) of proteins. 110 Further, this mark is recognized by PRC1 complex and it induces tightening of chromatin, repression of gene expression and is linked to stemness in cancer cells. 110 114 showed a role of USP28 as a type of deubiquitinase for a chromatin modulator LSD1. This study established that the epigenetic regulation by USP28 could be achieved through regulation of LSD1 expression and thus maintains the stemness traits in breast cancer. In another study, Yu et al. (2017) 115 suggested that SATB2, a transcription factor and an epigenetic regulator can directly bind to promoters of key genes, dedicated to pluripotency, cell survival and proliferation such as Bcl-2, c-Myc and Nanog, to induce dedifferentiation/transformation of mature HMECs into progenitor-like cells. In an epigenetic study, Shah et al. claimed that down regulation of tumor suppressor Homeobox gene HOXC8 is linked to DNA methylation at the gene promoter and expression of miR196 family members to enhance an increase in the CD441/CD24-/low cancer stem cell population with chemoresistance. 118 showed that enhanced activities of Wnt and histone deacetylase can reduce the expression of estrogen receptor 1 and progesterone receptor in breast cancer. Further, these data signify that concomitant blockade of Wnt, HDAC, and ESR1 using clinically relevant low-dose inhibitors could bring a change from CSCs to non-CSCs in TNBC cells. Recently, Witt et al. (2017) 119 suggested that specific histone deacetylases (HDACs) are associated to cancer stemness phenotype. To further delineate specific HDACs, they report that HDAC1 and HDAC7 play a significant role in CSCs maintenance. Further, their finding indicates that HDAC inhibitors (HDACi) targeting HDAC1 and HDAC7 are capable of precise targeting of CSCs.
DNA Repair Pathway and Drug Resistance
Stem cells of normal mammalian tissues including breast are described as non-specialized cells with unwritten blank pages provided with an ability to renew themselves through cell division and potency to differentiate during adverse situations including genomic insults. 14, 15 Efforts are underway to investigate potential behavior of BCSCs in response to genotoxic agents commonly used in patients to create genomic instability. Several experimental and preclinical studies point out that CSCs are difficult to be killed by anti-neoplastic agents. [11] [12] [13] [14] [15] [16] A widely accepted hallmark of cancer is genomic instability which is manifested possibly due to combined effect of DNA damage, tumour-specific DNA repair defects, and more recently in the context of genetic/epigenetic control of DNA repair pathways in CSCs. 11, 16, 24, 32, [120] [121] [122] An optimistic scenario is such aberration in DNA damage response pathway may also turn out as a platform for therapeutic opportunities. 15, 16, 19, 89, 121, 123 Further, Al-Assar et al. (2011) 124 provided substantial evidence to support that such BCSC population is credited with significantly more RAD51, proficient homologous recombination and less g-H2AX foci. The role of BMI1 is suggested in stem cell pluripotency and oncogenesis linked with ability to facilitate the repair of double-stranded breaks via homologous recombination (HR). 125 Recently, Lamb et al. (2015) 126 provided an experimental evidence to show that doxycycline drug may curtail DNA-PK protein expression by nearly 15-fold (>90%) in BCSCs. Levine et al. (2016) suggested that CSCs may require other p53-regulated functions including epigenetically controlled differentiation process mediated by mutations in p53 gene to confer stemness properties in cancer. 127, 128 Recently, Wang et al. (2016) 129 demonstrated that depletion of BRCA1 or FANCD2 (Fanconi anemia, FA proteins) or BRG1, amSWI/SNF subunit can cause human mammary epithelial (HME) cells to undergo spontaneous EMT and unexpected differentiation. Additional evidences also suggest that autophagy inhibitor chloroquine effectively targets BCSCs through autophagy inhibition, mitochondrial structural damage, and arrest of double-stranded DNA break repair pathway. 130, 131 In summary, not much is understood regarding the molecular mechanisms behind BCSCs role in tumor drug resistance and thus limiting approaches towards molecular therapy. Much remains to be discovered regarding the complex eluding signaling approaches adopted by BCSCs and look for combinatorial therapeutic approaches.
BCSCS and Therapeutic Eradication Approaches
In the past decade, several therapeutic strategies are highlighted and categorized as either directly targeting of CSCs or intercepting signals from its microenvironment. Although some therapies are sound, they have certain limitations like to side effects which perturb healthy tissue since CSCs niche is similar and close to that of normal stem cell niche. 11, 19, 22, 24 At the same time, prospects of these new therapies are being appreciated by bolstering the efficacy of existing drugs against aggressive cancers including breast carcinoma. It is widely accepted that precise locking down of BCSCs niches can stop tumor relapse and enhance patient survival. There are growing views that most of the employed chemo-radiation therapies do not destroy the origin of breast tumor as BCSCs are resistant to these therapeutic options. 19, 22, 52, 69, 122, 132, 133 Energy metabolism in HDAC inhibitor-induced stem-like cancer cells differed sharply from that of differentiated cell types. The potential of dual-therapy approach for targeting bulk differentiated cells with HDAC inhibitors and CSCs with G6PD inhibitors have been recently highlighted. 134 In recent, HDAC inhibitors like vorinostat, entinostat, romidepsin have been suggested to serve a better option compared to global DNA methylation inhibitor such as 5-azacytidine in preclinical and clinical cancer therapeutic study. [134] [135] [136] [137] In a recent study, entinostat a class I selective HDAC inhibitor has been shown to reduce the percentage of tumor initiating cells from TNBC. 136 Their findings conclude that entinostat treatment brings down CD441/CD24-/low cell population, ALDH-1 activity, and stemness markers such as Bmi-1, Nanog, and Oct-4.
136
Regarding breast cancer drug resistance, Saha et al. (2016) 138 reported that combined uses of aspirin with genotoxic drugs c (5-fluorouracil, doxorubicin, and cyclophosphamide) modulate the nuclear translocation of NF-jB in preexisting CSCs. Further, these findings support that aspirin and conventional chemotherapy together may help breast cancer patients and prevent relapse. Further, Samanta et al. have shown that the administration of HIF inhibitors along with paclitaxel can remove the resistance of BCSC to paclitaxel. 93 Another study shows the preclinical effects of Quinacrine (QC) with ABT-888, a PARP inhibitor by decreasing the growth of highly metastatic breast cancer stem cells (mBCSCs) possibly by activating APC and inhibiting base excision repair (BER). 139 A recent study shows that targeting CXCR2 signaling may help to circumvent therapy resistance in breast cancer due to contribution of CXCR2 signaling axis in breast tumor progression. 140 In the pursuit of inhibitor based drugs against BCSCs, recent reports signify that Mithramycin A, a known specificity protein (Sp)1 inhibitor can sensitize BCSCs by altering the expression of several key players providing growth and survival advantages.
141
A well-known melatonin hormone has been shown to participate in EMT by modulating the expression of key associated proteins in BCSCs 142 and it is also linked to inhibition of OCT-4 stemness gene. 143 Wahler et al. (2015) 144 report that vitamin D compound (BXL0124)may repress breast cancer stem cell-like population. Finally, these findings indicate that this compound may potentially contribute to breast carcinoma inhibition.
A recent work elucidates that miRNA-125a indirectly controls TAZ, an effector molecule in the Hippo pathway, through the leukemia inhibitory factor receptor (LIFR). Inhibition of miRNA-125a in breast cancer cells led to a significant reduction in the CSC pool and could be a potential target against BCSCs that may strengthen existing genotoxic drug based therapy. 145 Inhibition of phosphorylation of epidermal growth factor receptor (EGFR) by Gefitinib demonstrate that tumor vascularization of BCSCs is mediated by EGF/Hsp27 signaling and use of inhibitors as Gefitinib to EGF may benefit breast cancer therapy. 146 GSIXII (a g-secretase inhibitor) is reported to initiate programmed cell death by targeting BCSCs. The mechanism behind the action of GSIXII is suggested to be due to its ability to promote Bcl2-homology 3 domain (BH3)-antisurvival protein, NOXA that hinders Mcl-1 (a pro-survival protein) to stop mammary tumor formation. 147 Anti-Notch1 monoclonal antibodies (mAbs) bind particularly to the region of human Notch1. 148 A recent study suggests that 6-shogaol (a gingerderived compound) could kill BCSCs by decreasing expression levels of Cleaved Notch1, Hes1 and Cyclin D1. Further, authors suggest that g-secretase inhibitor in combination with 6-shogaol would enhance killing of breast cancer stem cells through suppression of Notch signaling. 149 MicroRNA-34a (miR-34a) is reported to inhibit growth, survival and metastatic ability of BCSCs by suppressing NOTCH1 downstream signaling pathway and could serve as a therapeutic approach in breast cancer.
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CWP232228 (a small-molecule inhibitor) a novel Wnt inhibitor inhibits association of b-catenin with T-cell factor (TCF) in the nucleus and b-catenin-mediated transcription inhibition resulting in inhibiting growth, self-renewal and differentiability of BCSCs. 151 Resveratrol (a natural polyphenolic compound) has also been suggested to stop the growth of BCSCs by inhibiting Wnt/b-catenin signaling pathway. 152 Pyrviniumpamoate abbreviated as (PP), an anti-helminthic drug is a recently discovered WNT pathway suppressor which stops growth of BCSCs and inhibits expression of stemness regulators like NANOG, SOX2 and OCT4 involved in regulation of breast cancer stem cell renewal characteristics. 153 Further, several plant secondary metabolites, including soy isoflavone genistein, green tea catechins are being investigated for their potential to sensitize BCSCs to standard chemotherapeutic drugs. 154, 155 Another class of natural compound as Genistein (isoflavone component present in soy products) has been documented to arrest growth and survival of BCSCs by blocking hedgehog downstream signaling. 156 A Huaier extract is reported to reduce growth, proliferation and selfrenewal properties of BCSCs and possibly to manifest as an inhibitor of hedgehog downstream signaling leading to apoptosis. 77 Additionally, a drug Salinomycin (Sal) is indicated to attenuate growth, metastasis and self-renewal properties of BCSCs by inhibiting Gli-1 and Smo mediated hedgehog signaling. 157 Thiostrepton (an antibiotic having thiazole ring) inhibits sonic Shh signaling by decreasing Gli-1 translocation into nucleus and elimination of mRNA in BCSCs serving as a therapeutic drug for elimination of BCSCs.
16 GANT61 (a non-canonical Hh inhibitor) in combination with antiestrogens reduced population of BCSCs in breast cancer tumor samples by inhibiting non-canonical hedgehog signaling. 158 Jiang et al. (2016) 159 have demonstrated that Glabridin (GLA), a phytochemical from the root of Glycyrrhiza glabra can reduce the CSC-like properties through microRNA-148a (miR-148a)/transforming growth factor-b (TGF-b)-SMAD2 signal pathway in in vitro cell culture and mouse xenograft model. There is another report on the ability of a novel triterpenoid, AECHL-1to curb the TGF-b/TNF-a induced EMT and characteristics of BCSC. 160 There is a report that metformin in combination with therapeutic drugs such as 5-fluouracil, epirubicin, and cyclophosphamide (FEC) can synergize in non-stem breast cancer cells and BCSCs. 161 Moreover, metformin is reported to represent a potential selective drug against BCSCs as an effective (neo-)adjuvant therapy. 162 This may act via miRNA-27 b controlled repression of ecto-nucleotide pyrophosphatase/ phosphodiesterase family member 1 (ENPP1). 163 Taken together, the surges in therapeutic options to silence BCSCs in tumors are highly appreciated. Among several class of drugs, synthetically designed inhibitors, mimicking drugs and naturally derived compounds have been surfaced to block the different genetic as well as epigenetically regulated signaling aspects of BCSCs self-renewal and tumor differentiation. In future, the efficacies, delivery and precision of these potential drugs should be taken into consideration for better responsiveness. A summary of molecular and clinical therapeutic interventions to BCSCs is presented in Supplementary material Table S1 and Figure 2 .
Conclusion and Future Prospects
Since the original notion about the CSC model in cancer growth, metastasis and drug resistance, the success stories are rising to understand the complex story of BCSCs for better clinical therapeutic responses. In recent, several avenues are documented to harness the therapeutic approaches including small non-coding RNA mimetics, small molecule inhibitors to key signaling pathways and DNA repair inhibitors. However, available drug development attempts have been focused in in vitro BCSCs based evaluation model. Such in vitro based drug development methods are faced with potential arguments that showing umpteen heterogeneity of BCSCs niche players including cytokines, miRNAs etc. in in vivo setting. An additional issue that needs to be taken care of is that that development of a drug against a type of breast cancer stem cell may not yield broader responses in different breast cancer stem cell types. So, there is a need to recapitulate and progress with drug development approaches to BCSCs by considering other reliable model such threedimensional tumor culture and appropriate animal models. In addition, another point is discussed that even animal model of mouse does not reflect the complete intricacies of intracellular signaling network as observed in human model. Hence, future development of primary human breast tumor xenograft in preferentially humanized mice is required to achieve the true representation of BCSCs subpopulation in almost similar physiological states compared between mouse and human. Despite tremendous progress in basic research and pre-clinical data in BCSCs, challenges that remained as obstacles for complete eradication of BCSCs are highlighted as lack of clinical evidence of signaling players, issue of precision based targeted therapy and clinical efficacy. 
